Shots:

• The company initiates P-III clinical trial to evaluate the efficacy- safety- tolerability- PK- and immunogenicity of SB17 vs Stelara in a ratio (1:1) in patients with moderate to severe plaque psoriasis
• Additionally- patients either continue on Stelara or transition to SB17 @28wks. The IPs (SB17 or Stelara- q12w) will be administered @0- 4 and for up to 40wks. and the last assessment will be performed @52wks.
• The company continues to advance a broad pipeline of biosimilar candidates covering therapeutic areas- including immunology- oncology- ophthalmology- hematology- endocrinology- and gastroenterology

Ref: PR Newswire | Image: Samsung Bioepis